{
    "clinical_study": {
        "@rank": "4827", 
        "arm_group": {
            "arm_group_label": "Subjects prescribed lamotrigine tablets", 
            "description": "Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome to whom lamotrigine tablets are administered."
        }, 
        "brief_summary": {
            "textblock": "The objectives of this post-marketing surveillance (PMS) are to grasp the actual use of\n      lamotrigine tablets to collect safety information in the long-term use according to seizure\n      type and concomitant antiepileptic drug (AED), and to confirm its efficacy."
        }, 
        "brief_title": "Special Drug Use Investigation for LAMICTAL (Lamotrigine) Tablets for Long-term Use", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Epilepsy", 
        "condition_browse": {
            "mesh_term": "Epilepsy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized\n             seizures of Lennox-Gastaut syndrome\n\n          -  Subjects who are treated with lamotrigine tablets\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Adult (>=15 to <65 years) and pediatric (>=2 to <15 years) subjects with epilepsy with\n        the following seizure type who use lamotrigine tablets\n\n          -  Partial seizures\n\n          -  Tonic-clonic seizures\n\n          -  Generalized seizures of Lennox-Gastaut syndrome"
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863602", 
            "org_study_id": "112728"
        }, 
        "intervention": {
            "arm_group_label": "Subjects prescribed lamotrigine tablets", 
            "description": "Administered for long-term according to the prescribing information in the locally approved label by the authorities.", 
            "intervention_name": "Lamotrigine tablets", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Lamotrigine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 23, 2013", 
        "number_of_groups": "1", 
        "official_title": "Special Drug Use Investigation for LAMICTAL (Lamotrigine) Tablets for Long-term Use", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The incidence of adverse drug reactions", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Presence or absence of skin disorder and its details after the start of treatment will be investigated as a priority investigation item", 
                "measure": "Occurrence of skin disorder after the start of treatment", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863602"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Investigators will assess the overall improvement as \"remarkably improved\". \"improved\", \"slightly improved\", \"unchanged\" or \"worsened\" on the basis of the degree of change in frequency of seizures, strength, span and other related symptoms.", 
            "measure": "Overall improvement of subjects' symptoms", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2009", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}